Recombinant human IGFBP-3 showed significant inhibition of tumor growth in trastuzumab resistant HER2 and IGF-1R overexpressing cell lines and in vivo synergistic interaction with antiHER2 therapy by decreasing bioavailability of IGF-1 ligand [11, 19]. This evidence concerns the gene ERBB2 and neoplasm.